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How big pharma and regulators fail 
clinicians
Generalists daily make poor 
evidence-based decisions 
because regulatory and ethics 
committees fail them and 
drug companies habitually 
misrepresent products. The pervasiveness 
of this perversion – at least overseas – is best 
illustrated by the equivalent of R131.4 billion 
in healthcare fraud settlements made by 
pharmaceutical corporates in the USA 
over the last 10 years, with the most recent 
individual company fines breaking all 
records.
Professor Keymanthri Moodley, head 
of the Centre for Medical Ethics and 
Law in the Faculty of Health Sciences 
at Stellenbosch University, revealed this 
while discussing challenges in the ethics 
of medical generalism at the 16th National 
Family Practitioners conference in 
Observatory, Cape Town, on 11 May this 
year. She said that one of the significant 
challenges in generalism was the growing 
base of easily accessible scientific data, of 
which a significant proportion is unreliable. 
The ability to critique this data was vital 
to evidence-based medicine, and doctors/
clinicians faced a major dilemma in sifting 
out what was falsely presented to them. 
Citing what she termed ‘a favourite book of 
mine’ (Bad Pharma by epidemiologist Ben 
Goldacre),[1] she said that positive findings 
were twice as likely to be published as 
negative findings, which Goldacre describes 
as ‘a cancer at the core of evidence-based 
medicine’. She said Goldacre outlined 
the myriad ways in which regulatory 
and research ethics committees let the 
profession down, while numerous studies 
involving routine treatments (she singled 
out antidepressants and statins) were deeply 
flawed and ‘presented in a skewed direction’. 
Goldacre estimates that 25% of the massive 
global turnover of the pharmaceutical 
industry goes to advertising and promotion, 
which translates inter alia to incentives to 
doctors in the form of gifts, promotional 
meetings and conferences, overseas travel 
expenses (including spouses and partners), 
sponsored hospital grand rounds and 
other clinical meetings, and even holidays. 
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Companies draft study protocols and 
trial results for lead investigators to sign 
off, with negative and non-supporting 
results buried and not published. Under 
such circumstances, doctors are no 
better than ordinary consumers, he says. 
Goldacre provides examples to show 
that the industry, profession, research 
ethics committees, medical journals and 
regulatory authorities lack vigilance in the 
design, conduct, analysis and interpretation 
of clinical studies.
Moodley said that, as a result, and in 
pursuit of evidence-based medicine, ‘we may 
sometimes do more harm than good to our 
patients’. She said it was getting worse, citing 
some of the most recent billion-dollar fines 
paid by major pharmaceutical companies in 
the USA, many of them repeat offenders who 
seemed to write off such punitive measures 
as ‘a mere cost of doing business’. On 2 July 
last year, GlaxoSmithKline (GSK) agreed to 
plead guilty to three criminal counts for 
sales of misbranded Paxil (paroxetine) and 
Wellbutrin (bupropion) – drugs promoted 
for indications for which they had not 
been approved by the FDA (aka off-label 
promotion). Under both criminal and civil 
charges, they paid today’s equivalent of 
R28.3 billion to the federal government and 
participating states. At the time this settlement 
was announced, 25 major companies and 
8 of the top 10 global pharmaceutical 
companies were under ‘corporate integrity 
agreements’, a routine part of settlements 
for healthcare fraud, typically requiring 
enhanced compliance activities within the 
company for 5 years, including reports to the 
government from an independent monitor. 
GSK also pleaded guilty to failing to report 
safety data on Avan dia (rosiglitazone) and 
violating the Food, Drug and Cosmetic 
Act. [2] A year earlier, biotechnology company 
Amgen paid R235  million in a settlement 
over whistleblower allegations that they 
paid kickbacks to longterm care pharmacies 
to increase the use of an anaemia drug in 
nursing homes. Amgen allegedly pressured 
pharmacists to recommend Aransep 
(darbepoetin alfa) for nursing home residents 
who did not have anaemia associated with 
chronic renal failure, and distributed materials 
and sponsored programmes promoting 
this off-label use of the medication. (The 
company denied all allegations as part of the 
settlement). In December last year, Amgen 
settled another suit for R7.187 billion and 
accepted a corporate integrity agreement. A 
third case against them is pending.[3]
Moodley said a second major challenge 
faced by generalists was their relationship 
with specialists. GPs found themselves at the 
centre of a network of specialists, medical 
funders, radiology and pathology companies 
and the pharmaceutical industry. Given this 
web of relationships, conflict was bound to 
arise. However, the basic guiding principles 
in generalist-specialist disagreements included 
patient welfare and best interests, and mutual 
integrity and respect. She urged more 
experienced doctors to become aware that 
they acted as ‘role models’ to students and 
young doctors who ‘watch us and will replicate 
inappropriate behaviour’. With generalism 
often regarded as ‘the stepsister’ in healthcare 
provision, inappropriate remarks were 
sometimes made by specialists with respect 
to generalist referral notes and generalists. She 
said it was vital that health resources were used 
‘appropriately and prudently,’ and referrals 
were one area where social relationships 
and specialist touting could contribute to 
suboptimal care. The ultimate responsibility 
for co-ordinating patient care lay with the 
referring doctor. ‘Increasingly problematic’ was 
specialists becoming the first point of contact 
for patients and actively encouraging patients 
to book appointments with them instead of 
via their GPs.
Another challenge for generalists was 
other professions taking on additional 
responsibilities, e.g. pharmacies that offered 
a wide and welcome range of screening tests 
but where pharmacists often indulged in 
diagnosis and therapeutics. ‘I often stand at 
the pharmacy counter and listen to people 
presenting symptoms in full earshot of all 
present, and I am amazed at how pharmacists 
come up with diagnoses (and then dispense 
without examining patients); I have to try 
very hard not to intervene.’ The ethos of 
medical generalism focused on empathy 
which she described as ‘the intelligent use of 
insight into the whole setting of the patient’s 
plight,’ engagement (or a commitment to 
active involvement in every aspect of the 
patient’s care), an appreciation of the GP’s 
limits (understanding and acknowledging 
the specialist aspect of care) and knowing 
when to refer a patient. Every GP also 
had to deal with ‘end of life’ issues; she 
emphasised the role of patient autonomy 
in exercising both the right to life and the 
right to a dignified death. Organisations 
across the globe, especially in Switzerland 
(Dignitas)[4] and Europe, had evolved where 
‘anyone with 10 000 Francs can go and 
deliberately choose to end their life, usually 
in the terminal phase of an illness’. ‘End of 
life/suicide tourism is a reality. It’s happening 
in a more transparent and powerful way than 
ever before. We’re all comfortable with a 
patient’s right to life but we need to deal with 
their right to end their lives when they so 
desire, especially in the context of terminal 
and debilitating illnesses,’ she added.
Dignitas offers assisted suicide to any 
member (including foreigners) suffering from 
a terminal or unendurable illness who wishes 
to end their life and suffering. They use a 
lethal, fast-acting and painless barbiturate 
dissolved in drinking water. Each permitted 
use of the medication requires a Swiss 
doctor’s prescription, an in-depth evaluation 
of the member’s written request and medical 
information, and at least two face-to-face 
meetings with Dignitas’ doctors. The member 
must be of sound judgement and possess a 
minimum level of physical mobility (sufficient 
to self-administer the drug).
Professor Moodley said her ‘take home’ 
messages were to critically appraise 
scientific evidence that guides generalist 
clinical care and to encourage teamwork 
in healthcare provision, ‘especially where 
generalists and specialists work together in a 
complementary manner with mutual respect 
and open communication for the benefit of 
the patient’.
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